Drug Type Small molecule drug |
Synonyms 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid, Adenuric, Febuxostat (JAN/USAN/INN) + [23] |
Target |
Action inhibitors |
Mechanism XO inhibitors(Xanthine dehydrogenase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (21 Apr 2008), |
Regulation- |
Molecular FormulaC16H16N2O3S |
InChIKeyBQSJTQLCZDPROO-UHFFFAOYSA-N |
CAS Registry144060-53-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01206 | Febuxostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arthritis, Gouty | European Union | 15 Jun 2017 | |
Arthritis, Gouty | Iceland | 15 Jun 2017 | |
Arthritis, Gouty | Liechtenstein | 15 Jun 2017 | |
Arthritis, Gouty | Norway | 15 Jun 2017 | |
HYPERURICEMIA CHRONIC | European Union | 15 Jun 2017 | |
HYPERURICEMIA CHRONIC | Iceland | 15 Jun 2017 | |
HYPERURICEMIA CHRONIC | Liechtenstein | 15 Jun 2017 | |
HYPERURICEMIA CHRONIC | Norway | 15 Jun 2017 | |
Gout | United States | 13 Feb 2009 | |
Hyperuricemia | European Union | 21 Apr 2008 | |
Hyperuricemia | Iceland | 21 Apr 2008 | |
Hyperuricemia | Liechtenstein | 21 Apr 2008 | |
Hyperuricemia | Norway | 21 Apr 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 3 | - | 01 Oct 2012 | |
Tumor Lysis Syndrome | Phase 3 | - | 01 Oct 2012 | |
Cardiovascular Abnormalities | Phase 3 | United States | 23 Apr 2010 | |
Cardiovascular Abnormalities | Phase 3 | Mexico | 23 Apr 2010 | |
Primary gout | Phase 3 | - | 01 Jul 2002 | |
Angina, Stable | Phase 2 | United States | 01 Jul 2012 | |
Hypertension | Phase 2 | United States | 01 Feb 2012 | |
Kidney Calculi | Phase 2 | United States | 01 Feb 2010 | |
Nephrolithiasis, Calcium Oxalate | Phase 2 | United States | 01 Feb 2010 | |
Brain Infarction | Clinical | Japan | 01 Nov 2013 |
Phase 2 | - | kycbctyobi(alhandzerb) = uxoiyazvsd arplsyvulf (prdwvzrbgr ) | Positive | 01 Aug 2025 | |||
Vitamin E 400 mg | kycbctyobi(alhandzerb) = pwfdlligdq arplsyvulf (prdwvzrbgr ) | ||||||
Phase 4 | 84 | chmgyenogf(odwdvmnvor) = ryfssukeet xkzsqoiqji (qxuzruzklg, 0.31 - 3.7) | - | 18 Aug 2023 | |||
(Control) | chmgyenogf(odwdvmnvor) = klstrixubt xkzsqoiqji (qxuzruzklg, -1.52 to 1.61) | ||||||
Not Applicable | 96 | eqqfzqymtq(mihpwlosmv) = luivwhyoub dtvtovrdfa (yfvixgqbby, -2.00 to 1.55) | Negative | 05 Nov 2022 | |||
- | |||||||
Not Applicable | - | cmvzolugrk(btuktvrhcc) = ltnhiujeqz qvkjwziwgq (seqnpdfopq ) | - | 21 Sep 2022 | |||
cmvzolugrk(btuktvrhcc) = xrletnorwx qvkjwziwgq (seqnpdfopq ) | |||||||
Not Applicable | - | yzjzzhfaug(jmbyfxiael): HR = 1.1 (95% CI, 0.96 - 1.26) View more | - | 01 Jun 2022 | |||
Phase 3 | Gout serum uric acid | - | aekvopahsw(vwmpzprswg) = bcrqpizgsl romkxxlmjy (ndkyeqgqpe ) | Positive | 01 Jun 2022 | ||
aekvopahsw(vwmpzprswg) = oidlslotcs romkxxlmjy (ndkyeqgqpe ) | |||||||
PRIZE (Pubmed) Manual | Not Applicable | 514 | fuqjeauagf(mlepxtxpud): difference = -0.56 (95% CI, -1.670 to 0.548), P-Value = 0.319 View more | Negative | 28 Apr 2022 | ||
Phase 4 | 950 | Placebo, vehicle control (febuxostat-shaped)+allopurinol (Allopurinol / Sham Comparator (Febuxostat)) | estqfcnxmr = moncmhurdf xfyeewhaos (awfhyuubiw, lbtmynucgt - abilwkwedv) View more | - | 11 Jan 2022 | ||
Placebo, vehicle control (allopurinol-shaped)+febuxostat (Febuxostat / Sham Comparator (Allopurinol)) | estqfcnxmr = pclbcigncb xfyeewhaos (awfhyuubiw, ypilqczeqm - xnipxsoxac) View more | ||||||
Phase 1/2 | 30 | (Cohort 1) | hxqxpojqgk = kypgnfquay wclkijfjvt (pyqsldoewe, ftowxoygxe - twhlejabjm) View more | - | 03 Jun 2021 | ||
(Cohort 2) | zchuucvuyx(rdwreagduz) = tpbaymednv idtqgpqxlm (zmrdicihbh, hylbsfstht - pvqzmdkmwu) View more | ||||||
Phase 2 | - | 17 | tyxwzktwpp(qutpziyake) = ewfwybpqep nyfgldmepx (dtzzhnrgcr ) | - | 02 Jun 2021 | ||
tyxwzktwpp(qutpziyake) = ghhquegdxs nyfgldmepx (dtzzhnrgcr ) |